Stemline Therapeutics, Inc. (STML) Posts Q1 Loss of 70c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Stemline Therapeutics (STML) PT Cut at Jefferies, Still Sees 288% Upside
May 19, 2014 8:15 AM EDTJefferies analyst Thomas Wei cut his price target on Stemline Therapeutics (NASDAQ: STML) to $50.00 (from $60.00) but reiterated a Buy rating as the new target still suggests 288% upside.
Wei comments, "STML has decided to revise its development program for SL-401 in acute... More
Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014
May 16, 2014 7:52 AM EDTRoth Capital affirms its Buy rating and $62 target price on Stemline Therapeutics (Nasdaq: STML) following the company's Q1 results, which were reported after markets closed Thursday.
Analyst Joseph Pantginis sees 2014 being a pivotal year for Stemline, commenting, We expect the initiation of three key studies, each of which could garner accelerated approval by the FDA (two studies with SL-401 and one study with SL-701). Based on... More
